Fig. 1From: Impact of continued administration of tolvaptan on cirrhotic patients with ascitesFlow chart of the study design. Overall, 170 cases with cirrhosis were treated with tolvaptan. Eight patients finished treatment due to improved ascites, and treatment was stopped in 90 cases due to poor condition, death, and liver transplantation. By contrast, 37 cases were continuously administered tolvaptan for ≥1 yearBack to article page